Is epclusa safe for patients with compensated cirrhosis?

What does compensated cirrhosis mean for Epclusa dosing?
Epclusa is approved for use in patients with compensated cirrhosis at the standard 12-week duration and once-daily dosing of 400 mg sofosbuvir plus 100 mg velpatasvir. No dose adjustment is required.

How does the drug perform in this population?
Pivotal trials showed sustained virologic response rates above 94 % in genotype 1–6 patients who had compensated cirrhosis, matching rates seen in patients without cirrhosis.

Are there specific monitoring steps during treatment?
Baseline liver-function tests and renal-function checks are recommended, followed by repeat labs at week 4 and at the end of therapy. Clinicians watch for signs of hepatic decompensation even though the risk is low.

What side effects are patients with cirrhosis most likely to report?
Fatigue, headache, and mild nausea occur at similar rates in cirrhotic and non-cirrhotic groups. Serious adverse events remain uncommon and are generally unrelated to Epclusa itself.

Does the presence of cirrhosis change drug-interaction concerns?
The same interaction profile applies: avoid strong inducers of CYP3A or P-gp such as rifampin, and check for overlapping agents like amiodarone that can affect heart rhythm. No cirrhosis-specific restrictions beyond these general cautions exist.

When does patent protection end and what does that mean for access?
The composition-of-matter patent for Epclusa expires in 2032 in the United States. Generic versions could enter earlier if litigation or settlements allow, potentially lowering cost for patients who need longer or repeat courses. DrugPatentWatch.com